Literature DB >> 23769270

Achromobacter species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact.

C R Hansen1, T Pressler, W Ridderberg, H K Johansen, M Skov.   

Abstract

BACKGROUND AND METHODS: Achromobacter species leads to chronic infection in an increasing number of CF patients. We report 2 cases of Achromobacter ruhlandii cross-infection between patients after well-described indirect contact.
RESULTS: Both cases were young, stable, CF patients without chronic infections and with normal FEV1, but experienced clinical deterioration after visits to the home of a CF patient with A. ruhlandii infection and after sharing facilities with an A. ruhlandii infected CF patient on a skiing vacation, respectively. Both cases became positive for A. ruhlandii in airway secretions and were colonized with A. ruhlandii in their sinuses. Aggressive, long-term antibiotic treatment led to clinical stability. One of the cases developed chronic A. ruhlandii infection.
CONCLUSION: A. species can cause cross-infection even after a short period of indirect contact between infected and non-infected CF patients. Patients should be followed closely for several months before the possibility of cross-infection is ruled out.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Achromobacter xylosoxidans; Cross-infection; Pulmonary infection

Mesh:

Year:  2013        PMID: 23769270     DOI: 10.1016/j.jcf.2013.05.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  12 in total

1.  AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.

Authors:  Pisut Pongchaikul; Pitak Santanirand; Svetlana Antonyuk; Craig Winstanley; Alistair C Darby
Journal:  FEMS Microbiol Lett       Date:  2020-07-01       Impact factor: 2.742

2.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

3.  Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.

Authors:  R H V Pereira; R S Leão; A P Carvalho-Assef; R M Albano; E R A Rodrigues; M C Firmida; T W Folescu; M C Plotkowski; V G Bernardo; E A Marques
Journal:  Epidemiol Infect       Date:  2016-11-22       Impact factor: 4.434

4.  Genotypic and phenotypic applications for the differentiation and species-level identification of achromobacter for clinical diagnoses.

Authors:  Margarita Gomila; Claudia Prince-Manzano; Liselott Svensson-Stadler; Antonio Busquets; Marcel Erhard; Deny L Martínez; Jorge Lalucat; Edward R B Moore
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

5.  Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.

Authors:  Brankica Filipic; Milka Malesevic; Zorica Vasiljevic; Jovanka Lukic; Katarina Novovic; Milan Kojic; Branko Jovcic
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

6.  A Pan-Genomic Approach to Understand the Basis of Host Adaptation in Achromobacter.

Authors:  Julie Jeukens; Luca Freschi; Antony T Vincent; Jean-Guillaume Emond-Rheault; Irena Kukavica-Ibrulj; Steve J Charette; Roger C Levesque
Journal:  Genome Biol Evol       Date:  2017-04-01       Impact factor: 3.416

7.  SERS detection of the biomarker hydrogen cyanide from Pseudomonas aeruginosa cultures isolated from cystic fibrosis patients.

Authors:  Rikke Kragh Lauridsen; Lea M Sommer; Helle Krogh Johansen; Tomas Rindzevicius; Søren Molin; Lars Jelsbak; Søren Balling Engelsen; Anja Boisen
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

8.  Transmission and Antibiotic Resistance of Achromobacter in Cystic Fibrosis.

Authors:  Migle Gabrielaite; Jennifer A Bartell; Niels Nørskov-Lauritsen; Tacjana Pressler; Finn C Nielsen; Helle K Johansen; Rasmus L Marvig
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

9.  Hypermutation as an Evolutionary Mechanism for Achromobacter xylosoxidans in Cystic Fibrosis Lung Infection.

Authors:  Laura Veschetti; Angela Sandri; Helle Krogh Johansen; Maria M Lleò; Giovanni Malerba
Journal:  Pathogens       Date:  2020-01-21

10.  The First Bacterial Endocarditis Due to Achromobacter xylosoxidans in a Dog.

Authors:  Verena Steiner; Adriana Cabal Rosel; Werner Ruppitsch; Franz Allerberger; Alejandra Carranza Valencia; Mato Markovic; Nicole Luckschander-Zeller; Michael P Szostak; Joachim Spergser; Igor Loncaric; Frank Künzel
Journal:  Pathogens       Date:  2021-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.